CHIMERIX

chimerix-logo

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. ... Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerixรขโ‚ฌโ„ขs extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.

#SimilarOrganizations #People #Financial #Event #Website #More

CHIMERIX

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2002-01-01

Address:
Durham, North Carolina, United States

Country:
United States

Website Url:
http://www.chimerix.com

Total Employee:
51+

Status:
Active

Contact:
9193136782

Email Addresses:
[email protected]

Total Funding:
441.25 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Font Awesome Domain Not Resolving Wordpress Plugins Sitelinks Search Box


Similar Organizations

axcella-logo

Axcella

Axcella is a biotechnology company providing therapeutics development solutions.

aztherapies-logo

AZTherapies

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

epivax-logo

EpiVax

EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.

immutep-logo

Immutep

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

iveric-bio-logo

IVERIC bio

IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.


Current Advisors List

ben-dubin_image

Ben Dubin Investor @ Chimerix
Advisor
2000-01-01

ernest-mario_image

Ernest Mario Chairman of the Board of Directors @ Chimerix
Board_member
2013-02-01

farah-champsi_image

Farah Champsi Board of Directors @ Chimerix
Board_member

wende-hutton_image

Wende Hutton Board Member @ Chimerix
Board_member

ronald-renaud_image

Ronald Renaud Member of the Board of Directors @ Chimerix
Board_member

martha-demski_image

Martha Demski Chair Of The Board Of Directors @ Chimerix
Board_member
2005-03-01

james-niedel_image

James Niedel Board Member @ Chimerix
Board_member

patrick-heron_image

Patrick Heron Board Member @ Chimerix
Board_member

Current Employees Featured

not_available_image

Christopher L. Jordan
Christopher L. Jordan Vice President Regulatory Affairs @ Chimerix
Vice President Regulatory Affairs
2022-08-01

michael-andriole_image

Michael Andriole
Michael Andriole CFO and Chief Business Officer @ Chimerix
CFO and Chief Business Officer
2019-01-01

mike-sherman_image

Mike Sherman
Mike Sherman Chief Executive Officer @ Chimerix
Chief Executive Officer

randall-lanier_image

Randall Lanier
Randall Lanier Chief Science Officer @ Chimerix
Chief Science Officer
2017-01-01

Founder


george-painter_image

George Painter

Stock Details


Company's stock symbol is NASDAQ:CMRX

Acquisitions List

Date Company Article Price
2021-01-08 Oncoceutics Oncoceutics acquired by Chimerix 78 M USD

Investors List

alta-partners_image

Alta Partners

Alta Partners investment in Series F - Chimerix

pappas-ventures_image

Pappas Ventures

Pappas Ventures investment in Series F - Chimerix

new-leaf-venture-partners_image

New Leaf Venture Partners

New Leaf Venture Partners investment in Series F - Chimerix

sanderling-ventures_image

Sanderling Ventures

Sanderling Ventures investment in Series F - Chimerix

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Series F - Chimerix

canaan-partners_image

Canaan Partners

Canaan Partners investment in Series F - Chimerix

asset-management-ventures_image

Asset Management Ventures (AMV)

Asset Management Ventures (AMV) investment in Series F - Chimerix

morningside-group_image

Morningside Group

Morningside Group investment in Series F - Chimerix

asset-management-ventures_image

Asset Management Ventures (AMV)

Asset Management Ventures (AMV) investment in Series E - Chimerix

alta-partners_image

Alta Partners

Alta Partners investment in Series E - Chimerix

Official Site Inspections

http://www.chimerix.com Semrush global rank: 95.54 K Semrush visits lastest month: 1.05 M

  • Host name: 172.67.43.91
  • IP address: 172.67.43.91
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Chimerix" on Search Engine